HC Wainwright Lifts Earnings Estimates for Cabaletta Bio

Cabaletta Bio, Inc. (NASDAQ:CABA) – Investment analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for Cabaletta Bio in a report released on Wednesday, April 1st. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.39) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for Cabaletta Bio’s current full-year earnings is ($2.34) per share. HC Wainwright also issued estimates for Cabaletta Bio’s Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.51) EPS, Q4 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.48) EPS, FY2028 earnings at ($1.41) EPS and FY2029 earnings at ($0.64) EPS.

Cabaletta Bio (NASDAQ:CABA) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.05.

CABA has been the topic of a number of other reports. Guggenheim lifted their target price on Cabaletta Bio from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Morgan Stanley reduced their price objective on shares of Cabaletta Bio from $14.00 to $13.00 and set an “overweight” rating for the company in a research report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cabaletta Bio in a research note on Wednesday, January 21st. Finally, Wall Street Zen raised Cabaletta Bio from a “strong sell” rating to a “hold” rating in a research report on Sunday, March 29th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Cabaletta Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Cabaletta Bio Stock Performance

CABA opened at $2.96 on Friday. The company has a market capitalization of $329.51 million, a PE ratio of -1.30 and a beta of 3.30. The stock’s fifty day moving average is $2.93 and its 200-day moving average is $2.58. Cabaletta Bio has a one year low of $0.99 and a one year high of $3.78.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of CABA. Invesco Ltd. raised its position in Cabaletta Bio by 357.1% during the first quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock valued at $85,000 after buying an additional 48,181 shares during the period. Comerica Bank boosted its position in Cabaletta Bio by 2,292.1% during the 1st quarter. Comerica Bank now owns 41,599 shares of the company’s stock worth $58,000 after acquiring an additional 39,860 shares during the period. AQR Capital Management LLC purchased a new position in Cabaletta Bio during the 1st quarter valued at about $102,000. XTX Topco Ltd acquired a new position in shares of Cabaletta Bio in the 2nd quarter valued at about $148,000. Finally, Marshall Wace LLP increased its holdings in shares of Cabaletta Bio by 470.7% in the 2nd quarter. Marshall Wace LLP now owns 190,957 shares of the company’s stock valued at $290,000 after purchasing an additional 157,497 shares during the period.

Insider Activity

In other news, CEO Steven Nichtberger purchased 45,000 shares of Cabaletta Bio stock in a transaction that occurred on Wednesday, January 21st. The stock was acquired at an average price of $2.24 per share, for a total transaction of $100,800.00. Following the transaction, the chief executive officer owned 1,031,483 shares in the company, valued at $2,310,521.92. The trade was a 4.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Shawn Tomasello acquired 22,725 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The stock was purchased at an average cost of $2.21 per share, with a total value of $50,222.25. Following the purchase, the director directly owned 22,725 shares in the company, valued at approximately $50,222.25. This trade represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 127,668 shares of company stock worth $286,211 in the last quarter. Insiders own 11.25% of the company’s stock.

Key Stories Impacting Cabaletta Bio

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised FY2026 EPS from ($1.89) to ($1.51), narrowing expected losses for the year — a meaningful improvement in the near?term outlook that supports higher valuation multiples for a small biotech. HC Wainwright raises FY2026 estimate
• Positive Sentiment: Quarterly 2026 estimates were also bumped: Q1–Q4 2026 EPS forecasts moved materially less negative (examples: Q1 from ($0.47) to ($0.39); Q2 from ($0.48) to ($0.40); Q3/Q4 to ~$0.36), reducing near?term cash?burn/loss expectations. HC Wainwright quarterly updates
• Positive Sentiment: HC Wainwright raised multi?year outlooks (FY2027, FY2028, FY2029) — e.g., FY2027 from ($1.97) to ($1.48); FY2028 from ($1.86) to ($1.41); FY2029 from ($0.92) to ($0.64) — signaling the analyst sees a clearer path to narrower losses and eventual profitability. HC Wainwright multi-year raises
• Neutral Sentiment: HC Wainwright published forward estimates for 2027–2030 (including a FY2030 EPS of $1.11), which provides a long?term revenue/profit scenario but depends on successful clinical/regulatory execution — useful for modeling but speculative. HC Wainwright long-term forecast
• Negative Sentiment: Despite the upgrades, consensus and company remain unprofitable this year (consensus FY current ~($2.34)/share) — ongoing clinical, regulatory and cash?burn risks mean upside from estimate revisions is not guaranteed. Consensus still negative
• Negative Sentiment: Cabaletta is a small, high?beta biotech (market cap ? $330M) so the stock can be volatile; analyst upgrades can spark short?term rallies but fundamental binary risks (trial readouts, regulatory news, financing) remain primary drivers. Risk/volatility context

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.